{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T18:32:58Z","timestamp":1789237978357,"version":"build-2803163510"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Previous studies have reported the mutational landscape in extramammary Paget disease (EMPD); however, the prognostic implications of genetic alterations remain unexplored. While CDKN2A loss is known to be associated with tumour progression or poor prognosis in some types of cancer, its significance in EMPD has not been investigated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To examine the association between common genetic alterations and prognosis in EMPD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A retrospective cohort study was carried out to analyse the data of patients with EMPD registered up to January 2024 in the Center for Cancer Genomics and Advanced Therapeutics database, a nationwide database that records clinical data and comprehensive genomic profiling (CGP) test results in Japan.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 167 patients with EMPD were recorded in the database, with CDKN2A loss being the most frequent genetic variant. Survival analysis was conducted on data from 127 patients. Survival from the initiation of chemotherapy was analysed, adjusting for length bias inherent in the database with the Kaplan\u2013Meier estimator, an established method of adjustment. Patients with BRCA2-mutant tumours (n = 18) had a worse prognosis than those with BRCA2 wildtype (WT) tumours [n = 109; hazard ratio (HR) 2.97, 95% confidence interval (CI) 1.46\u20136.01 (P = 0.003)]. Additionally, patients in the CDKN2A mutant group (n = 72) had a significantly worse prognosis compared with those in the CDKN2A WT group [n = 55; HR 1.81, 95% CI 1.06\u20133.07 (P = 0.029)]. Most CDKN2A variants were pathogenic, primarily characterized by loss, while most BRCA2 variants were variants of uncertain significance. In the survival analysis of CGP enrolment based on Eastern Cooperative Oncology Group performance status (ECOG-PS), patients with an ECOG-PS of 1 at the time of CGP enrolment had a significantly poorer prognosis compared with those with an ECOG-PS of 0 (P = 0.034; median survival time 531 vs. 259\u2005days).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>A somatic CDKN2A variant, mainly exhibiting loss, may be associated with a poor prognosis in EMPD. Patients with EMPD with BRCA2-mutant disease might also have a worse prognosis. In addition, CGP testing before ECOG-PS deteriorates is preferable, considering that the observed median survival of individuals undergoing CGP tests in an ECOG-PS 1 condition was &amp;lt; 9\u2005months.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bjd\/ljae337","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T23:28:24Z","timestamp":1724369304000},"page":"46-54","source":"Crossref","is-referenced-by-count":8,"title":["Association of genetic alterations with prognosis in extramammary Paget disease: insights into the involvement of somatic <i>CDKN2A<\/i> variants in patients with a poor prognosis"],"prefix":"10.1093","volume":"192","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3918-9803","authenticated-orcid":false,"given":"Okuto","family":"Iwasawa","sequence":"first","affiliation":[{"name":"Department of Dermatology, Graduate School of Medicine, The University of Tokyo , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masachika","family":"Ikegami","sequence":"additional","affiliation":[{"name":"Department of Musculoskeletal Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital , Tokyo ,","place":["Japan"]},{"name":"Division of Cellular Signaling, National Cancer Center Research Institute , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4471-1635","authenticated-orcid":false,"given":"Takuya","family":"Miyagawa","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Graduate School of Medicine, The University of Tokyo , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromichi","family":"Morita","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Graduate School of Medicine, The University of Tokyo , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hinako","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Graduate School of Medicine, The University of Tokyo , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issei","family":"Omori","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Graduate School of Medicine, The University of Tokyo , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Awaji","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Graduate School of Medicine, The University of Tokyo , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Omatsu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Graduate School of Medicine, The University of Tokyo , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Graduate School of Medicine, The University of Tokyo , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Kage","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsutoshi","family":"Oda","sequence":"additional","affiliation":[{"name":"Division of Integrative Genomics, Graduate School of Medicine, The University of Tokyo , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Graduate School of Medicine, The University of Tokyo , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0531-559X","authenticated-orcid":false,"given":"Hayakazu","family":"Sumida","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Graduate School of Medicine, The University of Tokyo , Tokyo ,","place":["Japan"]},{"name":"Scleroderma Center, The University of Tokyo Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,22]]},"reference":[{"key":"2024122223530275600_ljae337-B1","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3389\/fonc.2018.00038","article-title":"Metastatic extramammary Paget's disease: pathogenesis and novel therapeutic approach","volume":"8","author":"Fukuda","year":"2018","journal-title":"Front Oncol"},{"key":"2024122223530275600_ljae337-B2","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/DSS.0000000000002064","article-title":"Extramammary Paget disease: a review of the literature \u2013 Part I: History, epidemiology, pathogenesis, presentation, histopathology, and diagnostic work-up","volume":"46","author":"Morris","year":"2020","journal-title":"Dermatol Surg"},{"key":"2024122223530275600_ljae337-B3","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/DSS.0000000000002240","article-title":"Extramammary Paget's disease: a review of the literature Part II: Treatment and Prognosis","volume":"46","author":"Morris","year":"2020","journal-title":"Dermatol Surg"},{"key":"2024122223530275600_ljae337-B4","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1158\/1078-0432.CCR-20-3205","article-title":"Unbiased detection of driver mutations in extramammary Paget disease","volume":"27","author":"Ishida","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2024122223530275600_ljae337-B5","first-page":"PO.20.00073","article-title":"Genomic alterations as potential therapeutic targets in extramammary Paget's disease of the vulva","volume":"4","author":"Stasenko","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"2024122223530275600_ljae337-B6","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jdermsci.2019.03.006","article-title":"Identification of genetic alterations in extramammary Paget disease using whole exome analysis","volume":"94","author":"Kiniwa","year":"2019","journal-title":"J Dermatol Sci"},{"key":"2024122223530275600_ljae337-B7","first-page":"PO.19.00291","article-title":"Precision oncology and the universal health coverage system in Japan","volume":"3","author":"Ebi","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"2024122223530275600_ljae337-B8","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.jaad.2023.11.057","article-title":"Mutational landscape of advanced extramammary Paget disease with comprehensive genomic profiling tests: a cohort study in a Japanese real-world setting","volume":"90","author":"Iwasawa","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2024122223530275600_ljae337-B9","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1001\/jamaoncol.2021.5153","article-title":"Implications of selection bias due to delayed study entry in clinical genomic studies","volume":"8","author":"Brown","year":"2022","journal-title":"JAMA Oncol"},{"key":"2024122223530275600_ljae337-B10","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/cas.15651","article-title":"Selection bias due to delayed comprehensive genomic profiling in Japan","volume":"114","author":"Tamura","year":"2023","journal-title":"Cancer Sci"},{"key":"2024122223530275600_ljae337-B11","doi-asserted-by":"crossref","first-page":"801219","DOI":"10.3389\/fonc.2021.801219","article-title":"Deletion leading to hematogenous metastasis of human gastric carcinoma","volume":"11","author":"Qiao","year":"2021","journal-title":"Front Oncol"},{"key":"2024122223530275600_ljae337-B12","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ccell.2018.05.014","article-title":"Bi-allelic loss of CDKN2A initiates melanoma invasion via BRN2 activation","volume":"34","author":"Zeng","year":"2018","journal-title":"Cancer Cell"},{"key":"2024122223530275600_ljae337-B13","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s40478-023-01690-y","article-title":"CDKN2A\/B deletions are strongly associated with meningioma progression: a meta-analysis of individual patient data","volume":"11","author":"Wach","year":"2023","journal-title":"Acta Neuropathol Commun"},{"key":"2024122223530275600_ljae337-B14","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1080\/07853890.2018.1564359","article-title":"Prognostic significance of CDKN2A\/B deletions in acute lymphoblastic leukaemia: a meta-analysis","volume":"51","author":"Zhang","year":"2019","journal-title":"Ann Med"},{"key":"2024122223530275600_ljae337-B15","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s40478-023-01573-2","article-title":"P16 immunohistochemistry is a sensitive and specific surrogate marker for CDKN2A homozygous deletion in gliomas","volume":"11","author":"Vij","year":"2023","journal-title":"Acta Neuropathol Commun"},{"key":"2024122223530275600_ljae337-B16","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/NEN.0000000000000188","article-title":"CDKN2A loss is associated with shortened overall survival in lower-grade (World Health Organization Grades II\u2013III) astrocytomas","volume":"74","author":"Reis","year":"2015","journal-title":"J Neuropathol Exp Neurol"},{"key":"2024122223530275600_ljae337-B17","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/1097-0215(20001115)88:4<554::AID-IJC6>3.0.CO;2-Q","article-title":"CDKN2A\/p16 inactivation in the prognosis of oligodendrogliomas","volume":"88","author":"Bortolotto","year":"2000","journal-title":"Int J Cancer"},{"key":"2024122223530275600_ljae337-B18","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1177\/0962280218817573","article-title":"Transformation model estimation of survival under dependent truncation and independent censoring","volume":"28","author":"Chiou","year":"2019","journal-title":"Stat Methods Med Res"},{"key":"2024122223530275600_ljae337-B19","article-title":"A package for survival analysis in R","author":"Therneau"},{"key":"2024122223530275600_ljae337-B20","doi-asserted-by":"crossref","first-page":"1025367","DOI":"10.3389\/fonc.2023.1025367","article-title":"Comprehensive genomic profiling: Does timing matter?","volume":"13","author":"Thapa","year":"2023","journal-title":"Front Oncol"},{"key":"2024122223530275600_ljae337-B21","doi-asserted-by":"crossref","first-page":"e2323336","DOI":"10.1001\/jamanetworkopen.2023.23336","article-title":"First-line genomic profiling in previously untreated advanced solid tumors for identification of targeted therapy opportunities","volume":"6","author":"Matsubara","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2024122223530275600_ljae337-B22","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/bjd.20135","article-title":"Efficacy of S-1 plus docetaxel in the treatment of metastatic extramammary Paget's disease: a multicentre retrospective study","volume":"185","author":"Matsushita","year":"2021","journal-title":"Br J Dermatol"},{"key":"2024122223530275600_ljae337-B23","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/1346-8138.13200","article-title":"Usefulness of docetaxel as first-line chemotherapy for metastatic extramammary Paget's disease","volume":"43","author":"Yoshino","year":"2016","journal-title":"J Dermatol"},{"key":"2024122223530275600_ljae337-B24","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s10147-014-0686-2","article-title":"Combination chemotherapy of low-dose 5-fluorouracil and cisplatin for advanced extramammary Paget's disease","volume":"20","author":"Tokuda","year":"2015","journal-title":"Int J Clin Oncol"},{"key":"2024122223530275600_ljae337-B25","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/bjd.17922","article-title":"Single-agent taxane is useful in palliative chemotherapy for advanced extramammary Paget disease: a case series","volume":"181","author":"Kato","year":"2019","journal-title":"Br J Dermatol"},{"key":"2024122223530275600_ljae337-B26","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1111\/bjd.12788","article-title":"Combination chemotherapy for metastatic extramammary Paget disease","volume":"170","author":"Oashi","year":"2014","journal-title":"Br J Dermatol"},{"key":"2024122223530275600_ljae337-B27","doi-asserted-by":"crossref","first-page":"e15017","DOI":"10.1111\/exd.15017","article-title":"Proposal for the optimal staging of extramammary Paget's disease: a retrospective analysis of 57 cases with distant metastasis","volume":"33","author":"Funakoshi","year":"2024","journal-title":"Exp Dermatol"},{"key":"2024122223530275600_ljae337-B28","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jdermsci.2016.06.004","article-title":"A proposal for a TNM staging system for extramammary Paget disease: retrospective analysis of 301 patients with invasive primary tumors","volume":"83","author":"Ohara","year":"2016","journal-title":"J Dermatol Sci"},{"key":"2024122223530275600_ljae337-B29","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.3390\/cancers13153719","article-title":"Missense variants of uncertain significance: a powerful genetic tool for function discovery with clinical implications","volume":"13","author":"Sessa","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2024122223530275600_ljae337-B30","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41436-018-0018-4","article-title":"Comprehensive annotation of BRCA1 and BRCA2 missense variants by functionally validated sequence-based computational prediction models","volume":"21","author":"Hart","year":"2019","journal-title":"Genet Med"},{"key":"2024122223530275600_ljae337-B31","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"key":"2024122223530275600_ljae337-B32","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.3390\/cancers14133266","article-title":"Predominance of BRCA2 mutation and estrogen receptor positivity in unselected breast cancer with BRCA1 or BRCA2 mutation","volume":"14","author":"Pujol","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2024122223530275600_ljae337-B33","doi-asserted-by":"crossref","first-page":"3768247","DOI":"10.1155\/2017\/3768247","article-title":"Mammary and extramammary Paget's disease presented different expression pattern of \u00adsteroid\u00a0hormone receptors","volume":"2017","author":"Zhou","year":"2017","journal-title":"Biomed Res Int"},{"key":"2024122223530275600_ljae337-B34","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13053-024-00283-7","article-title":"Two Japanese families with familial pancreatic cancer with suspected pathogenic variants of CDKN2A: a case report","volume":"22","author":"Kiyozumi","year":"2024","journal-title":"Hered Cancer Clin Pract"},{"key":"2024122223530275600_ljae337-B35","doi-asserted-by":"crossref","first-page":"1276009","DOI":"10.3389\/fonc.2023.1276009","article-title":"Next-generation sequencing identifies CDKN2A alterations as prognostic biomarkers in recurrent or metastatic head and neck squamous cell carcinoma predominantly receiving immune checkpoint inhibitors","volume":"13","author":"Xue","year":"2023","journal-title":"Front Oncol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljae337\/59640487\/ljae337.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/192\/1\/46\/59640487\/ljae337.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/192\/1\/46\/59640487\/ljae337.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,22]],"date-time":"2024-12-22T23:53:16Z","timestamp":1734911596000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/192\/1\/46\/7738979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,22]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,8,22]]},"published-print":{"date-parts":[[2024,12,23]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljae337","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,8,22]]}}}